BACKGROUND: Although broadly neutralizing antibodies (bNAbs) have been shown to block a diverse array of cell-free human immunodeficiency type 1 (HIV-1) infections, it remains unclear whether these antibodies exhibit similar potency against mature dendritic cell (mDC)-mediated HIV-1 trans-infection. METHODS: Sensitivity to bNAbs targeting HIV-1 envelope surface unit gp120 (VRCO1, PG16, b12, and 2G12) and transmembrane domain gp41 (4E10 and 2F5) was examined for both cell-free and mDC-mediated infections of TZM-bl and CD4(+) T cells. RESULTS: Compared with cell-free infection, mDC-mediated infection was significantly less susceptible to gp120-directed bNAbs for the majority of virus isolates. A b12 antigen-binding fragment blocked both cell-free and mDC-mediated infection with equal efficiency. In contrast, cell-free and mDC-associated viruses were equally sensitive to gp41-directed bNAbs. Anti-gp41 bNAbs bound to the surface of mDCs and localized at the mDC-T cell synaptic junctions in the absence of virus. CONCLUSIONS: Anti-gp41 bNAbs have the potential to inhibit mDC-mediated HIV-1 infection because they bind plasma membranes prior to the formation of an infectious synapse, positioning them to neutralize subsequent virus transfer. As opposed to gp120-directed antibodies, anti-gp41 bNAbs might prevent HIV-1 infection if transmission or spread at the initial site of invasion occurs from a DC-associated source.
BACKGROUND: Although broadly neutralizing antibodies (bNAbs) have been shown to block a diverse array of cell-free humanimmunodeficiency type 1 (HIV-1) infections, it remains unclear whether these antibodies exhibit similar potency against mature dendritic cell (mDC)-mediated HIV-1 trans-infection. METHODS: Sensitivity to bNAbs targeting HIV-1 envelope surface unit gp120 (VRCO1, PG16, b12, and 2G12) and transmembrane domain gp41 (4E10 and 2F5) was examined for both cell-free and mDC-mediated infections of TZM-bl and CD4(+) T cells. RESULTS: Compared with cell-free infection, mDC-mediated infection was significantly less susceptible to gp120-directed bNAbs for the majority of virus isolates. A b12 antigen-binding fragment blocked both cell-free and mDC-mediated infection with equal efficiency. In contrast, cell-free and mDC-associated viruses were equally sensitive to gp41-directed bNAbs. Anti-gp41 bNAbs bound to the surface of mDCs and localized at the mDC-T cell synaptic junctions in the absence of virus. CONCLUSIONS: Anti-gp41 bNAbs have the potential to inhibit mDC-mediated HIV-1 infection because they bind plasma membranes prior to the formation of an infectious synapse, positioning them to neutralize subsequent virus transfer. As opposed to gp120-directed antibodies, anti-gp41 bNAbs might prevent HIV-1 infection if transmission or spread at the initial site of invasion occurs from a DC-associated source.
Authors: Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer Journal: AIDS Date: 2010-01-16 Impact factor: 4.177
Authors: S Munir Alam; Marco Morelli; S Moses Dennison; Hua-Xin Liao; Ruijun Zhang; Shi-Mao Xia; Sophia Rits-Volloch; Li Sun; Stephen C Harrison; Barton F Haynes; Bing Chen Journal: Proc Natl Acad Sci U S A Date: 2009-11-11 Impact factor: 11.205
Authors: Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton Journal: J Virol Date: 2009-11-11 Impact factor: 5.103
Authors: Lautaro G Perez; Matthew R Costa; Christopher A Todd; Barton F Haynes; David C Montefiori Journal: J Virol Date: 2009-05-20 Impact factor: 5.103
Authors: Nuria Izquierdo-Useros; Mar Naranjo-Gómez; Jacob Archer; Steven C Hatch; Itziar Erkizia; Julià Blanco; Francesc E Borràs; Maria Carmen Puertas; John H Connor; Maria Teresa Fernández-Figueras; Landon Moore; Bonaventura Clotet; Suryaram Gummuluru; Javier Martinez-Picado Journal: Blood Date: 2008-10-22 Impact factor: 22.113
Authors: Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton Journal: Science Date: 2009-09-03 Impact factor: 47.728
Authors: Philip R Johnson; Bruce C Schnepp; Jianchao Zhang; Mary J Connell; Sean M Greene; Eloisa Yuste; Ronald C Desrosiers; K Reed Clark Journal: Nat Med Date: 2009-05-17 Impact factor: 53.440
Authors: Randi B Gombos; Dror Kolodkin-Gal; Leila Eslamizar; Joshua O Owuor; Emanuele Mazzola; Ana M Gonzalez; Birgit Korioth-Schmitz; Rebecca S Gelman; David C Montefiori; Barton F Haynes; Joern E Schmitz Journal: J Virol Date: 2015-05-20 Impact factor: 5.103
Authors: Hisashi Akiyama; Caitlin Miller; Hiren V Patel; Steven C Hatch; Jacob Archer; Nora-Guadalupe P Ramirez; Suryaram Gummuluru Journal: J Virol Date: 2014-05-28 Impact factor: 5.103
Authors: Cheryl A Stoddart; Sofiya A Galkina; Pheroze Joshi; Galina Kosikova; Brian R Long; Ekaterina Maidji; Mary E Moreno; Jose M Rivera; Ukina R Sanford; Barbara Sloan; Witold Cieplak; Terri Wrin; Po-Ying Chan-Hui Journal: Virology Date: 2014-06-25 Impact factor: 3.616